Danaher (DHR) 10-Q 19 Oct 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 29, 2017	Oct. 13, 2017
Document And Entity Information [Abstract]
Document type	10-Q
Amendment flag	false
Document period end date	Sep. 29, 2017
Document fiscal year focus	2,017
Document fiscal period focus	Q3
Trading symbol	dhr
Entity registrant name	DANAHER CORP /DE/
Entity central index key	313,616
Current fiscal year end date	--12-31
Entity filer category	Large Accelerated Filer
Entity common stock, shares outstanding		695,605,257

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) shares in Millions, $ in Millions	Sep. 29, 2017	Dec. 31, 2016
Current assets:
Cash and equivalents	$ 648.6	$ 963.7
Trade accounts receivable, net	3,254.6	3,186.1
Inventories:
Finished goods	1,007.3	884.4
Work in process	325.1	299.4
Raw materials	559.9	525.6
Total inventories	1,892.3	1,709.4
Prepaid expenses and other current assets	464.7	805.9
Total current assets	6,260.2	6,665.1
Property, plant and equipment, net of accumulated depreciation of $2,373.3 and $1,963.3, respectively	2,424.9	2,354
Other long-term assets	689.1	631.3
Goodwill	24,783.8	23,826.9
Other intangible assets, net	11,693.3	11,818
Total assets	45,851.3	45,295.3
Current liabilities:
Notes payable and current portion of long-term debt	182.2	2,594.8
Trade accounts payable	1,501.8	1,485
Accrued expenses and other liabilities	2,703.5	2,794.2
Total current liabilities	4,387.5	6,874
Other long-term liabilities	5,356.4	5,670.3
Long-term debt	10,726.8	9,674.2
Stockholders' Equity:
Common stock - $0.01 par value, 2.0 billion shares authorized; 811.4 and 807.7 issued; 695.5 and 692.2 outstanding, respectively	8.1	8.1
Additional paid-in capital	5,472	5,312.9
Retained earnings	22,047.1	20,703.5
Accumulated other comprehensive income (loss)	(2,151.8)	(3,021.7)
Total Danaher stockholders' equity	25,375.4	23,002.8
Noncontrolling interests	5.2	74
Total stockholders' equity	25,380.6	23,076.8
Total liabilities and stockholders' equity	45,851.3	45,295.3
Property, plant and equipment, accumulated depreciation	$ 2,373.3	$ 1,963.3
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000	2,000
Common stock, shares issued	811.4	807.7
Common stock, shares outstanding	695.5	692.2

Consolidated Condensed Statemen

Consolidated Condensed Statements Of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016		Sep. 29, 2017	Sep. 30, 2016
Income Statement [Abstract]
Sales	$ 4,528.2	$ 4,132.1		$ 13,244	$ 12,298.1
Cost of sales	(1,991.4)	(1,846.1)		(5,890.6)	(5,463.5)
Gross profit	2,536.8	2,286		7,353.4	6,834.6
Operating costs:
Selling, general and administrative expenses	(1,490.1)	(1,345.8)		(4,448.4)	(4,105.2)
Research and development expenses	(279.2)	(241.1)		(829.9)	(707.1)
Operating profit	767.5	699.1		2,075.1	2,022.3
Nonoperating income (expense):
Other income	0	0		0	223.4
Loss on early extinguishment of borrowings	0	(178.8)		0	(178.8)
Interest expense	(39.9)	(43.7)		(120.9)	(152.1)
Interest income	2.2	0.1		5.6	0.1
Earnings from continuing operations before income taxes	729.8	476.7		1,959.8	1,914.9
Income taxes	(157.7)	(74.1)		(346.6)	(508.5)
Net earnings from continuing operations	572.1	402.6		1,613.2	1,406.4
Earnings from discontinued operations, net of income taxes	0	(11)		22.3	400.3
Net earnings	$ 572.1	$ 391.6		$ 1,635.5	$ 1,806.7
Net earnings per share:
Net earnings per share from continuing operations, basic (in dollars per share)	$ 0.82	$ 0.58		$ 2.32	$ 2.04
Net earnings per share from continuing operations, diluted (in dollars per share)	0.81	0.57		2.29	2.01
Net earnings per share from discontinued operations, basic (in dollars per share)	0	(0.02)		0.03	0.58
Net earnings per share from discontinued operations, diluted (in dollars per share)	0	(0.02)		0.03	0.57
Net earnings per share, basic (dollars per share)	0.82	0.57	[1]	2.35	2.62
Net earnings per share, diluted (dollars per share)	$ 0.81	$ 0.56	[1]	$ 2.32	$ 2.59	[1]
Average common stock and common equivalent shares outstanding:
Basic (shares)	696.2	692.2		695.3	690.6
Diluted (shares)	705.6	701.3		705.5	699.1
[1]	* Net earnings per share amounts do not add due to rounding.

Consolidated Condensed Stateme4

Consolidated Condensed Statements Of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net earnings	$ 572.1	$ 391.6	$ 1,635.5	$ 1,806.7
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	260	275.6	839.2	314.8
Pension and postretirement plan benefit adjustments	4.6	4.7	14.4	15.8
Unrealized gain (loss) on available-for-sale securities adjustments	(1.9)	8.8	16.3	(121.5)
Total other comprehensive income (loss), net of income taxes	262.7	289.1	869.9	209.1
Comprehensive income	$ 834.8	$ 680.7	$ 2,505.4	$ 2,015.8

Consolidated Condensed Stateme5

Consolidated Condensed Statement Of Stockholders' Equity - 9 months ended Sep. 29, 2017 - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Beginning balance, shares at Dec. 31, 2016		807.7
Beginning balance, amount at Dec. 31, 2016	$ 23,076.8	$ 8.1	$ 5,312.9	$ 20,703.5	$ (3,021.7)	$ 74
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period	1,635.5			1,635.5
Other comprehensive income	869.9				869.9
Dividends declared				(291.9)
Common stock-based award activity, shares		3.7
Common stock-based award activity, amount		$ 0	159.3
Common stock issued in connection with LYONs’ conversions, including tax benefit, shares		0
Common stock issued in connection with LYONs’ conversions, including tax benefit, amount		$ 0	1
Change in noncontrolling interests			(1.2)			(68.8)
Ending balance, shares at Sep. 29, 2017		811.4
Ending balance, amount at Sep. 29, 2017	$ 25,380.6	$ 8.1	$ 5,472	$ 22,047.1	$ (2,151.8)	$ 5.2

Consolidated Condensed Stateme6

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net earnings	$ 1,635.5	$ 1,806.7
Less: earnings from discontinued operations, net of income taxes	(22.3)	(400.3)
Net earnings from continuing operations	1,613.2	1,406.4
Noncash items:
Depreciation	427.3	395.9
Amortization	492.9	426.6
Stock-based compensation expense	104.8	96.3
Restructuring and impairment charges	49.3	0
Pretax loss on early extinguishment of borrowings	0	(178.8)
Pretax gain on sale of investments	0	(223.4)
Change in trade accounts receivable, net	74.6	(94.8)
Change in inventories	(98.2)	(138.5)
Change in trade accounts payable	(48.5)	(38.1)
Change in prepaid expenses and other assets	242.3	171.9
Change in accrued expenses and other liabilities	(214.6)	257.4
Total operating cash provided by continuing operations	2,643.1	2,438.5
Total operating cash provided by discontinued operations	0	434.3
Net cash provided by operating activities	2,643.1	2,872.8
Cash flows from investing activities:
Cash paid for acquisitions	(112)	(99.6)
Payments for additions to property, plant and equipment	(445.8)	(422.1)
Proceeds from sales of property, plant and equipment	32.3	7.2
Proceeds from sale of investments	0	264.8
All other investing activities	(2.4)	0
Total investing cash used in continuing operations	(527.9)	(249.7)
Total investing cash used in discontinued operations	0	(69.8)
Net cash used in investing activities	(527.9)	(319.5)
Cash flows from financing activities:
Proceeds from the issuance of common stock	49	156.6
Payment of dividends	(281)	(313.3)
Payment for purchase of noncontrolling interests	(64.4)	0
Make-whole premiums to redeem borrowings prior to maturity	0	188.1
Net repayments of borrowings (maturities of 90 days or less)	(3,319.1)	(2,334.2)
Proceeds from borrowings (maturities longer than 90 days)	1,684	3,240.9
Repayments of borrowings (maturities longer than 90 days)	(562.4)	(2,354.2)
All other financing activities	(50.7)	(26.7)
Total financing cash used in continuing operations	(2,544.6)	(1,819)
Cash distributions to Fortive, net	0	(485.3)
Net cash used in financing activities	(2,544.6)	(2,304.3)
Effect of exchange rate changes on cash and equivalents	114.3	(68.4)
Net change in cash and equivalents	(315.1)	180.6
Beginning balance of cash and equivalents	963.7	790.8
Ending balance of cash and equivalents	648.6	971.4
Supplemental disclosures:
Cash interest payments	117.4	199.4
Cash income tax payments	378.3	330.8
Distribution of noncash net assets to Fortive Corporation	$ 0	$ (1,983.6)

General

General	9 Months Ended
	Sep. 29, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	GENERAL The consolidated condensed financial statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries or the consolidated subsidiaries of Danaher Corporation, as the context requires. Unless otherwise indicated, all amounts in this quarterly report refer to continuing operations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The consolidated condensed financial statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2016 and the Notes thereto included in the Company’s Current Report on Form 8-K filed on June 19, 2017 and the 2016 Annual Report on Form 10-K filed on February 22, 2017 (collectively, the “2016 Annual Report”) . In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of September 29, 2017 and December 31, 2016 , its results of operations for the three and nine -month periods ended September 29, 2017 and September 30, 2016 and its cash flows for each of the nine -month periods then ended. Accumulated Other Comprehensive Income (Loss) —The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. Foreign Currency Translation Adjustments Pension & Postretirement Plan Benefit Adjustments Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments Total For the Three-Month Period Ended September 29, 2017: Balance, June 30, 2017 $ (1,819.0 ) $ (632.4 ) $ 36.9 $ (2,414.5 ) Other comprehensive income (loss) before reclassifications: Increase (decrease) 260.0 — (3.0 ) 257.0 Income tax impact — — 1.1 1.1 Other comprehensive income (loss) before reclassifications, net of income taxes 260.0 — (1.9 ) 258.1 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 7.0 (a) — 7.0 Income tax impact — (2.4 ) — (2.4 ) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 4.6 — 4.6 Net current period other comprehensive income (loss), net of income taxes 260.0 4.6 (1.9 ) 262.7 Balance, September 29, 2017 $ (1,559.0 ) $ (627.8 ) $ 35.0 $ (2,151.8 ) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 7 for additional details. Foreign Currency Translation Adjustments Pension & Postretirement Plan Benefit Adjustments Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments Total For the Three-Month Period Ended September 30, 2016: Balance, July 1, 2016 $ (1,758.2 ) $ (636.2 ) $ 3.2 $ (2,391.2 ) Other comprehensive income (loss) before reclassifications: Increase 275.6 — 13.9 289.5 Income tax impact — — (5.1 ) (5.1 ) Other comprehensive income (loss) before reclassifications, net of income taxes 275.6 — 8.8 284.4 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 7.2 (a) — 7.2 Income tax impact — (2.5 ) — (2.5 ) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 4.7 — 4.7 Net current period other comprehensive income (loss), net of income taxes 275.6 4.7 8.8 289.1 Distribution of Fortive Corporation (83.5 ) 63.3 (c) — (20.2 ) Balance, September 30, 2016 $ (1,566.1 ) $ (568.2 ) $ 12.0 $ (2,122.3 ) For the Nine-Month Period Ended September 29, 2017: Balance, December 31, 2016 $ (2,398.2 ) $ (642.2 ) $ 18.7 $ (3,021.7 ) Other comprehensive income (loss) before reclassifications: Increase 839.2 — 26.1 865.3 Income tax impact — — (9.8 ) (9.8 ) Other comprehensive income (loss) before reclassifications, net of income taxes 839.2 — 16.3 855.5 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 22.2 (a) — 22.2 Income tax impact — (7.8 ) — (7.8 ) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 14.4 — 14.4 Net current period other comprehensive income (loss), net of income taxes 839.2 14.4 16.3 869.9 Balance, September 29, 2017 $ (1,559.0 ) $ (627.8 ) $ 35.0 $ (2,151.8 ) For the Nine-Month Period Ended September 30, 2016: Balance, December 31, 2015 $ (1,797.4 ) $ (647.3 ) $ 133.5 $ (2,311.2 ) Other comprehensive income (loss) before reclassifications: Increase 314.8 — 28.8 343.6 Income tax impact — — (10.7 ) (10.7 ) Other comprehensive income (loss) before reclassifications, net of income taxes 314.8 — 18.1 332.9 Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 23.6 (a) (223.4 ) (b) (199.8 ) Income tax impact — (7.8 ) 83.8 76.0 Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 15.8 (139.6 ) (123.8 ) Net current period other comprehensive income (loss), net of income taxes 314.8 15.8 (121.5 ) 209.1 Distribution of Fortive Corporation (83.5 ) 63.3 (c) — (20.2 ) Balance, September 30, 2016 $ (1,566.1 ) $ (568.2 ) $ 12.0 $ (2,122.3 ) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 7 for additional details. (b) Included in other income in the accompanying Consolidated Condensed Statement of Earnings. Refer to Note 10 for additional details. (c) This accumulated other comprehensive income (loss) component included an income tax impact of $21 million . New Accounting Standards —In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which provided clarity on which changes to the terms or conditions of share-based payment awards require an entity to apply the modification accounting provisions required in Topic 718. The standard is effective for all entities for annual periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company does not expect the adoption of this ASU will have a material impact on its consolidated financial statements. In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost , which requires employers to disaggregate the service cost component from other components of net periodic benefit costs and to disclose the amounts of net periodic benefit costs that are included in each income statement line item. The standard requires employers to report the service cost component in the same line item as other compensation costs and to report the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. The income statement guidance requires application on a retrospective basis. The ASU is effective for public entities for annual periods beginning after December 15, 2017, including interim periods, with early adoption permitted. The Company does not expect the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718) , which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification of certain items on the statement of cash flows and accounting for forfeitures. The Company has adopted this standard effective January 1, 2017. The ASU requires that the difference between the actual tax benefit realized upon exercise or vesting, as applicable, and the tax benefit recorded based on the fair value of the stock award at the time of grant (the “excess tax benefits”) be reflected as a reduction of the current period provision for income taxes with any shortfall recorded as an increase in the tax provision rather than as a component of changes to additional paid-in capital. The ASU also requires the excess tax benefit realized be reflected as operating cash flow rather than a financing cash flow. For the three and nine -month periods ended September 29, 2017 , the provision for income taxes from continuing operations was reduced and operating cash flow from continuing operations was increased by $7 million and $40 million , respectively, reflecting the impact of adopting this standard. Had this ASU been adopted at January 1, 2016, the provision for income taxes from continuing operations would have been reduced and operating cash flow from continuing operations would have been increased by $8 million and $34 million from the amounts reported for the three and nine -month periods ended September 30, 2016 , respectively. The actual benefit to be realized in future periods is inherently uncertain and will vary based on the price of the Company’s common stock as well as the timing of and relative value realized for future share-based transactions. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which requires lessees to recognize a right-of-use asset and a lease liability for all leases with terms greater than 12 months. The standard also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. The ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. In September 2017, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which provided additional implementation guidance on the previously issued ASU . Management has not yet completed its assessment of the impact of the new standard on the Company’s consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The ASU amends guidance on the classification and measurement of financial instruments, including significant revisions in accounting related to the classification and measurement of investments in equity securities and presentation of certain fair value changes for financial liabilities when the fair value option is elected. The ASU requires equity securities to be measured at fair value with changes in fair value recognized through net earnings and amends certain disclosure requirements associated with the fair value of financial instruments. The ASU is effective for the Company on January 1, 2018. In the period of adoption, the Company is required to reclassify the unrealized gains/losses on equity securities within accumulated other comprehensive income (loss) to retained earnings, which is not expected to be material to the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , which supersedes nearly all existing revenue recognition guidance. The core principle of Topic 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of the standard by one year which results in the new standard being effective for the Company at the beginning of its first quarter of fiscal year 2018. In addition, during March, April, May and December 2016 and September 2017, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, and ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), respectively, which clarified the guidance on certain items such as reporting revenue as a principal versus agent, identifying performance obligations, accounting for intellectual property licenses, assessing collectability, presentation of sales taxes, impairment testing for contract costs, disclosure of performance obligations, and provided additional implementation guidance. The Company plans to adopt the new standard on January 1, 2018. The Company has completed its initial assessment of the effect of adoption. Based on this assessment, the Company expects the impact of the new standard on the amount and timing of revenue recognition to be insignificant. The new standard will require certain costs, primarily sales-related commissions on contracts greater than one year in duration, to be capitalized rather than expensed currently. The new standard will also require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows from customer contracts, including judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The Company has identified, and is in the process of implementing, appropriate changes to its business processes, systems and controls to support recognition and disclosure under the new standard. The Company expects to use the modified retrospective method of adoption, reflecting the cumulative effect of initially applying the new standard to revenue recognition in the first quarter of 2018.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 29, 2017
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS For a description of the Company’s acquisition activity for the year ended December 31, 2016 reference is made to the financial statements as of and for the year ended December 31, 2016 and Note 2 thereto included in the Company’s 2016 Annual Report. The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses, anticipated opportunities for synergies from the elimination of redundant facilities and staffing and use of each party’s respective, existing commercial infrastructure to cost-effectively expand sales of the other party’s products and services, and the complementary strategic fit and resulting synergies these businesses bring to existing operations. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-acquisition contingencies associated with certain of its 2017 and 2016 acquisitions and is also in the process of obtaining valuations of certain property, plant and equipment, acquired intangible assets and certain acquisition-related liabilities in connection with these acquisitions. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required. During the first nine months of 2017 , the Company acquired five businesses for total consideration of $112 million in cash, net of cash acquired. The businesses acquired complement existing units of the Life Sciences and Environmental & Applied Solutions segments. The aggregate annual sales of these five businesses at the time of their respective acquisitions, in each case based on the company’s revenues for its last completed fiscal year prior to the acquisition, were approximately $70 million . The Company preliminarily recorded an aggregate of $73 million of goodwill related to these acquisitions. The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for all acquisitions consummated during the nine -month period ended September 29, 2017 ($ in millions): Trade accounts receivable $ 8.7 Inventories 13.2 Property, plant and equipment 4.9 Goodwill 73.2 Other intangible assets, primarily customer relationships, trade names and technology 52.5 Trade accounts payable (4.1 ) Other assets and liabilities, net (36.4 ) Net cash consideration $ 112.0 Acquisition of Noncontrolling Interest In the first quarter of 2017, Danaher acquired the remaining noncontrolling interest associated with one of its prior business combinations for consideration of $64 million . Danaher recorded the increase in ownership interests as a transaction within stockholders’ equity. As a result of this transaction, noncontrolling interests were reduced by $63 million reflecting the carrying value of the interest with the $1 million difference charged to additional paid-in capital. Pro Forma Financial Information The unaudited pro forma information for the periods set forth below gives effect to the 2017 and 2016 acquisitions as if they had occurred as of January 1, 2016 . The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Sales $ 4,528.5 $ 4,327.2 $ 13,269.4 $ 12,883.7 Net earnings from continuing operations 572.1 367.8 1,613.2 1,287.2 Diluted net earnings per share from continuing operations 0.81 0.53 2.29 1.84 In the nine -month period ended September 30, 2016 , unaudited pro forma earnings set forth above were adjusted to include the $23 million pretax impact of nonrecurring acquisition date fair value adjustments to inventory and deferred revenue primarily related to the 2016 acquisition of Cepheid.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 29, 2017
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONS Fortive Corporation Separation On July 2, 2016 (the “Distribution Date”), Danaher completed the separation (the “Separation”) of Fortive Corporation (“Fortive”) . For additional details on the Separation reference is made to the financial statements as of and for the year ended December 31, 2016 and Note 3 thereto included in the Company’s 2016 Annual Report. The accounting requirements for reporting the Separation of Fortive as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying consolidated condensed financial statements for all periods presented reflect this business as a discontinued operation. In connection with the Separation, Danaher and Fortive entered into various agreements to effect the Separation and provide a framework for their relationship after the Separation, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement and a Danaher Business System (“DBS”) license agreement. These agreements provide for the allocation between Danaher and Fortive of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after Fortive’s separation from Danaher and govern certain relationships between Danaher and Fortive after the Separation. In addition, Danaher is party to various commercial agreements with Fortive entities. The amounts billed for transition services provided under the above agreements as well as commercial sales and purchases to and from Fortive were not material to the Company’s results of operations for the three or nine -month periods ended September 29, 2017 . In the nine-month period ended September 29, 2017 , Danaher recorded a $22 million income tax benefit related to the release of previously provided reserves associated with uncertain tax positions on certain Danaher tax returns which were jointly filed with Fortive entities. These reserves were released due to the expiration of statutes of limitations for those returns. All Fortive entity-related balances were included in the income tax benefit related to discontinued operations. The key components of income from discontinued operations for the three-month period ended September 30, 2016 and the nine -month periods ended September 29, 2017 and September 30, 2016 were as follows ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 30, 2016 September 29, 2017 September 30, 2016 Sales $ — $ — $ 3,029.8 Cost of sales — — (1,566.4 ) Selling, general and administrative expenses (16.4 ) — (696.0 ) Research and development expenses — — (190.4 ) Interest expense — — (19.7 ) Earnings from discontinued operations before income taxes (16.4 ) — 557.3 Income taxes 5.4 22.3 (157.0 ) Earnings from discontinued operations, net of income taxes $ (11.0 ) $ 22.3 $ 400.3

Goodwill

Goodwill	9 Months Ended
	Sep. 29, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	GOODWILL The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2016 $ 23,826.9 Attributable to 2017 acquisitions 73.2 Adjustments due to finalization of purchase price allocations (71.3 ) Foreign currency translation and other 955.0 Balance, September 29, 2017 $ 24,783.8 The carrying value of goodwill by segment is summarized as follows ($ in millions): September 29, 2017 December 31, 2016 Life Sciences $ 12,153.9 $ 11,610.3 Diagnostics 7,049.0 6,903.0 Dental 3,341.1 3,215.6 Environmental & Applied Solutions 2,239.8 2,098.0 Total $ 24,783.8 $ 23,826.9 The Company has not identified any “triggering” events which indicate a potential impairment of goodwill in the nine -month period ended September 29, 2017 .

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 29, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total September 29, 2017: Assets: Available-for-sale securities $ 143.6 $ 47.1 $ — $ 190.7 Liabilities: Deferred compensation plans — 59.3 — 59.3 December 31, 2016: Assets: Available-for-sale securities $ 117.8 $ 52.3 $ — $ 170.1 Liabilities: Deferred compensation plans — 52.2 — 52.2 Available-for-sale securities, which are included in other long-term assets in the accompanying Consolidated Condensed Balance Sheets, are either measured at fair value using quoted market prices in an active market or if they are not traded on an active market are valued at quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. The Company has established nonqualified deferred compensation programs that permit officers, directors and certain management employees to defer a portion of their compensation, on a pretax basis, until at or after their termination of employment (or board service, as applicable). All amounts deferred under such plans are unfunded, unsecured obligations of the Company and are presented as a component of the Company’s compensation and benefits accrual included in other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Participants may choose among alternative earning rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program (except that the earnings rates for amounts deferred by the Company’s directors and amounts contributed unilaterally by the Company are entirely based on changes in the value of the Company’s common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates. Fair Value of Financial Instruments The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): September 29, 2017 December 31, 2016 Carrying Amount Fair Value Carrying Amount Fair Value Assets: Available-for-sale securities $ 190.7 $ 190.7 $ 170.1 $ 170.1 Liabilities: Notes payable and current portion of long-term debt 182.2 182.2 2,594.8 2,594.8 Long-term debt 10,726.8 11,181.4 9,674.2 10,095.1 As of September 29, 2017 and December 31, 2016 , available-for-sale securities were categorized as Level 1 and Level 2, as indicated above, and short and long-term borrowings were categorized as Level 1. The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings (other than the Company’s Liquid Yield Option Notes due 2021 (the “LYONs”)) is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. In the case of the LYONs, differences in the fair value from the carrying value are attributable to changes in the price of the Company’s common stock due to the LYONs’ conversion features. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable approximate their carrying amounts due to the short-term maturities of these instruments.

Financing

Financing	9 Months Ended
	Sep. 29, 2017
Debt Disclosure [Abstract]
Financing	FINANCING As of September 29, 2017 , the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions): September 29, 2017 December 31, 2016 U.S. dollar-denominated commercial paper $ 190.0 $ 2,733.5 Euro-denominated commercial paper (€2.3 billion and €3.0 billion, respectively) 2,692.1 3,127.6 Floating rate senior unsecured notes due 2017 (€500.0 million aggregate principal amount) (the “2017 Euronotes”) — 526.0 0.0% senior unsecured bonds due 2017 (CHF 100.0 million aggregate principal amount) (the “2017 CHF Bonds”) 103.1 98.0 1.65% senior unsecured notes due 2018 499.0 498.1 1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”) 706.9 628.6 2.4% senior unsecured notes due 2020 497.5 496.8 5.0% senior unsecured notes due 2020 398.5 402.6 Zero-coupon Liquid Yield Option Notes (LYONs) due 2021 68.7 68.1 0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) 265.7 255.6 1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”) 940.5 836.5 Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) 294.4 — 0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”) 559.6 532.3 2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”) 940.5 836.8 3.35% senior unsecured notes due 2025 496.2 495.8 0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) 272.5 — 1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”) 702.8 — 1.125% senior unsecured bonds due 2028 (CHF 110.0 million aggregate principal amount) (the “2028 CHF Bonds”) 114.4 108.8 0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) 470.6 — 4.375% senior unsecured notes due 2045 499.3 499.3 Other 196.7 124.6 Total debt 10,909.0 12,269.0 Less: currently payable 182.2 2,594.8 Long-term debt $ 10,726.8 $ 9,674.2 For additional details regarding the Company’s debt financing, reference is made to Note 9 of the Company’s financial statements as of and for the year ended December 31, 2016 included in the Company’s 2016 Annual Report. The Company satisfies any short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. Credit support for the commercial paper programs is generally provided by the Company’s $4.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on July 10, 2020 (the “Credit Facility”), which can also be used for working capital and other general corporate purposes. In October 2016, the Company expanded its borrowing capacity by entering into a $3.0 billion 364-day unsecured revolving credit facility with a syndicate of banks that expires on October 23, 2017 (the “364-Day Facility” and together with the Credit Facility, the “Credit Facilities”), to provide additional liquidity support for issuances under the Company’s U.S. dollar and euro-denominated commercial paper programs. Effective April 21, 2017, the Company reduced the commitment amount under the 364-Day Facility from $3.0 billion to $2.3 billion , and effective June 23, 2017, the Company further reduced the commitment amount under the facility to $1.0 billion , as permitted by the facility. As of September 29, 2017 , no borrowings were outstanding under the Credit Facilities, and the Company was in compliance with all covenants thereunder. In addition to the Credit Facilities, the Company has also entered into reimbursement agreements with various commercial banks to support the issuance of letters of credit. As of September 29, 2017 , borrowings outstanding under the Company’s U.S. dollar and euro-denominated commercial paper programs had a weighted average annual interest rate of negative 0.2% and a weighted average remaining maturity of approximately 64 days. The Company has classified approximately $2.9 billion of its borrowings outstanding under the commercial paper programs as of September 29, 2017 as long-term debt in the accompanying Consolidated Condensed Balance Sheet as the Company had the intent and ability, as supported by availability under the Credit Facility, to refinance these borrowings for at least one year from the balance sheet date. Debt discounts, premiums and debt issuance costs totaled $31 million and $25 million as of September 29, 2017 and December 31, 2016 , respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above. 2017 Long-Term Debt Issuances On May 11, 2017, DH Japan Finance S.A. (“Danaher Japan”), a wholly-owned finance subsidiary of the Company, completed the private placement of ¥30.8 billion aggregate principal amount of 0.3% senior unsecured notes due May 11, 2027 (the “2027 Yen Notes”) and ¥53.2 billion aggregate principal amount of 0.65% senior unsecured notes due May 11, 2032 (the “2032 Yen Notes” and together with the 2027 Yen Notes, the “Yen Notes”). The Yen Notes were issued at 100% of their principal amount. The Yen Notes are fully and unconditionally guaranteed by the Company. The Company received net proceeds, after offering expenses, of approximately ¥83.6 billion (approximately $744 million based on currency exchange rates as of the date of the pricing of the notes ) and used the net proceeds from the offering to partially repay commercial paper borrowings. Interest on the Yen Notes is payable semiannually in arrears on May 11 and November 11 of each year, commencing on November 11, 2017. On June 30, 2017, DH Europe Finance S.A. (“Danaher International”), a wholly-owned finance subsidiary of the Company, completed the underwritten public offering of €250 million aggregate principal amount of floating rate, senior unsecured notes due 2022 (the “2022 Floating Rate Euronotes”) and €600 million aggregate principal amount of 1.2% senior unsecured notes due 2027 (the “2027 Euronotes” and together with the 2022 Floating Rate Euronotes, the “Euronotes”). The 2022 Floating Rate Euronotes were issued at 100.147% of their principal amount, will mature on June 30, 2022 and bear interest at a floating rate equal to three-month EURIBOR plus 0.3% per year (provided that the minimum interest rate is zero ). The 2027 Euronotes were issued at 99.682% of their principal amount, will mature on June 30, 2027 and bear interest at the rate of 1.2% per year. The Euronotes are fully and unconditionally guaranteed by the Company. The Company received net proceeds, after underwriting discounts and commissions and offering expenses, of €843 million (approximately $940 million based on currency exchange rates as of the date of the pricing of the notes ) and used the net proceeds from the offering to repay the €500 million aggregate principal amount of floating rate senior unsecured notes which matured on June 30, 2017 as well as to repay commercial paper borrowings. Interest on the 2022 Floating Rate Euronotes is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, commencing on September 30, 2017. Interest on the 2027 Euronotes is payable annually in arrears on June 30 of each year, commencing on June 30, 2018. The note purchase agreement under which the Yen Notes were issued, and the indenture under which the Euronotes were issued, each contain customary covenants, all of which the Company was in compliance with as of September 29, 2017 . If a change of control triggering event occurs with respect to the Euronotes or the Yen Notes, each holder of such notes may require the Company to repurchase some or all of its notes at a purchase price equal to 101% (in the case of the Euronotes) or 100% (in the case of the Yen Notes) of the principal amount of the notes, plus accrued and unpaid interest (and in the case of the Yen Notes, certain swap-related losses as applicable). A change of control triggering event means the occurrence of both a change of control and a rating event, each as defined in the applicable indenture or note purchase agreement. Each holder of the Yen Notes may also require the Company to repurchase some or all of its notes at a purchase price equal to 100% of the principal amount of the notes, plus accrued and unpaid interest and certain swap-related losses as applicable, in certain circumstances whereby such holder comes into violation of economic sanctions laws as a result of holding such notes. At any time and from time to time prior to March 30, 2027 (three months prior to the maturity date of the 2027 Notes), the Company may redeem the 2027 Notes, in whole or in part, by paying the principal amount and a “make-whole” premium, plus accrued and unpaid interest. In addition, on or after March 30, 2027, the Company will have the right, at its option, to redeem the 2027 Notes, in whole or in part, at any time and from time to time, by paying the principal amount plus accrued and unpaid interest. At any time and from time to time, the Company may redeem the Yen Notes, in whole or in part, by paying the principal amount and a “make-whole” premium, plus accrued and unpaid interest and net of certain swap-related gains or losses as applicable. The Company may also redeem the Euronotes and the Yen Notes upon the occurrence of specified, adverse changes in tax laws, or interpretations under such laws, at a redemption price equal to the principal amount of the notes to be redeemed. 2017 Long-Term Debt Repayments The €500 million aggregate principal amount of floating rate senior unsecured notes due in 2017 were repaid upon their maturity in June 2017. Guarantors of Debt Danaher has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The 2017 Euronotes, 2019 Euronotes, 2022 Euronotes, 2022 Floating Rate Euronotes, 2025 Euronotes and 2027 Euronotes were issued by Danaher International. The 2017 CHF Bonds, 2023 CHF Bonds and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”), a wholly-owned finance subsidiary of the Company. The 2021 Yen Notes, 2027 Yen Notes and 2032 Yen Notes were issued by Danaher Japan. All securities issued by each of Danaher International, Danaher Switzerland and Danaher Japan are fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness. LYONs Redemption During the nine -month period ended September 29, 2017 , holders of certain of the Company’s LYONs converted such LYONs into an aggregate of approximately 27 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s deferred tax liability associated with the book and tax basis difference in the converted LYONs was transferred to additional paid-in capital as a result of the conversions.

Defined Benefit Plans

Defined Benefit Plans	9 Months Ended
	Sep. 29, 2017
Defined Benefit Plan [Abstract]
Defined Benefit Plans	DEFINED BENEFIT PLANS The following sets forth the components of the Company’s net periodic benefit cost of the noncontributory defined benefit pension plans ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 U.S. Pension Benefits: Service cost $ 1.9 $ 2.2 $ 5.7 $ 6.8 Interest cost 20.1 22.3 62.1 67.7 Expected return on plan assets (32.4 ) (33.0 ) (98.2 ) (99.6 ) Amortization of actuarial loss 5.9 6.3 19.1 18.3 Curtailment gain recognized — — — (0.7 ) Net periodic pension cost $ (4.5 ) $ (2.2 ) $ (11.3 ) $ (7.5 ) Non-U.S. Pension Benefits: Service cost $ 8.1 $ 9.0 $ 23.7 $ 26.9 Interest cost 6.7 8.4 19.5 25.8 Expected return on plan assets (10.8 ) (9.9 ) (31.5 ) (30.8 ) Amortization of actuarial loss 2.0 1.9 5.8 8.5 Amortization of prior service credit (0.1 ) (0.1 ) (0.3 ) (0.3 ) Settlement loss recognized — — — 0.1 Net periodic pension cost $ 5.9 $ 9.3 $ 17.2 $ 30.2 The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee benefit plans ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Service cost $ 0.1 $ 0.2 $ 0.5 $ 0.6 Interest cost 1.1 1.4 3.7 4.2 Amortization of actuarial (gain) loss — (0.1 ) — 0.1 Amortization of prior service credit (0.8 ) (0.8 ) (2.4 ) (2.4 ) Net periodic benefit cost $ 0.4 $ 0.7 $ 1.8 $ 2.5 Net periodic pension and benefit costs are included in cost of sales and selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. Employer Contributions During 2017 , the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are expected to be approximately $55 million and $40 million , respectively. The ultimate amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates and other factors.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 29, 2017
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company’s effective tax rate from continuing operations for the three and nine -month periods ended September 29, 2017 was 21.6% and 17.7% , respectively, as compared to 15.5% and 26.6% for the three and nine -month periods ended September 30, 2016 , respectively. The Company’s effective tax rate for 2017 and 2016 differs from the U.S. federal statutory rate of 35.0% due principally to the Company’s earnings outside the United States that are indefinitely reinvested and taxed at rates lower than the U.S. federal statutory rate. The effective tax rate for the nine-month period ended September 29, 2017 includes a benefit from the release of reserves upon the expiration of statutes of limitations and audit settlements, excess tax benefits from stock-based compensation, as well as higher tax benefits from restructuring charges that are predominantly in the United States, which in aggregate decreased the reported tax rate by 3.3% . The effective tax rate for the three and nine-month periods ended September 30, 2016 includes a higher tax rate associated with the loss on the early extinguishment of borrowings during the third quarter of 2016 which lowered the effective tax rate by 6.0% and 1.0% , respectively. The effective tax rate for the nine-month periods ended September 30, 2016 also includes charges related to the repatriation of earnings and legal entity realignments associated with the Separation and higher tax rate on the gain from sale of marketable equity securities which in aggregate increased the effective tax rate by 6.6% . Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries. On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) totaling approximately DKK 1.5 billion including interest through September 29, 2017 (approximately $235 million based on the exchange rate as of September 29, 2017 ), imposing withholding tax relating to interest accrued in Denmark on borrowings from certain of the Company’s subsidiaries for the years 2004-2009. The Company is currently in discussions with SKAT and anticipates receiving an assessment for years 2010-2012 totaling approximately DKK 874 million including interest through September 29, 2017 (approximately $139 million based on the exchange rate as of September 29, 2017 ). Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is vigorously defending its positions. The Company appealed these assessments to the National Tax Tribunal in 2014 and intends on pursuing this matter through the European Court of Justice should this appeal be unsuccessful. The ultimate resolution of this matter is uncertain, could take many years, and could result in a material adverse impact to the Company’s financial statements, including its effective tax rate.

Stock Transactions And Stock-Ba

Stock Transactions And Stock-Based Compensation	9 Months Ended
	Sep. 29, 2017
Share-based Compensation [Abstract]
Stock Transactions And Stock-Based Compensation	STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the nine -month period ended September 29, 2017 . On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. As of September 29, 2017 , 20 million shares remained available for repurchase pursuant to the Repurchase Program. For a full description of the Company’s stock-based compensation programs, reference is made to Note 17 of the Company’s financial statements as of and for the year ended December 31, 2016 included in the Company’s 2016 Annual Report. As of September 29, 2017 , approximately 72 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan. The following summarizes the components of the Company’s stock-based compensation expense ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Restricted stock units (“RSUs”)/performance stock units (“PSUs”): Pretax compensation expense $ 21.9 $ 21.1 $ 67.6 $ 65.0 Income tax benefit (6.6 ) (6.2 ) (20.7 ) (19.1 ) RSU/PSU expense, net of income taxes 15.3 14.9 46.9 45.9 Stock options: Pretax compensation expense 11.5 10.3 37.2 31.3 Income tax benefit (3.6 ) (3.2 ) (11.8 ) (9.7 ) Stock option expense, net of income taxes 7.9 7.1 25.4 21.6 Total stock-based compensation: Pretax compensation expense 33.4 31.4 104.8 96.3 Income tax benefit (10.2 ) (9.4 ) (32.5 ) (28.8 ) Total stock-based compensation expense, net of income taxes $ 23.2 $ 22.0 $ 72.3 $ 67.5 Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. As of September 29, 2017 , $153 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two years . As of September 29, 2017 , $129 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately three years . Future compensation amounts will be adjusted for any changes in estimated forfeitures. The Company realized a tax benefit of $15 million and $64 million in the three and nine -month periods ended September 29, 2017 , respectively, related to the exercise of employee stock options and vesting of RSUs. As a result of the adoption of ASU 2016-09, Compensation—Stock Compensation , the excess tax benefit of $7 million and $40 million for the three and nine -month periods ended September 29, 2017 , respectively, has been recorded as a reduction to the current income tax provision and is reflected as an operating cash inflow in the accompanying Consolidated Condensed Statement of Cash Flows. Prior to the adoption of ASU 2016-09, the excess tax benefit was recorded as an increase to additional paid-in capital and was reflected as a financing cash flow.

Nonoperating Income (Expense)

Nonoperating Income (Expense)	9 Months Ended
	Sep. 29, 2017
Component of Operating Income [Abstract]
Nonoperating Income (Expense)	NONOPERATING INCOME (EXPENSE) The Company received $265 million of cash proceeds from the sale of marketable equity securities during the first quarter of 2016. The Company recorded a pretax gain related to this sale of $223 million ( $140 million after-tax or $0.20 per diluted share) during the nine -month period ended September 30, 2016 . In the third quarter of 2016, the Company redeemed approximately $1.9 billion in aggregate principal amount of outstanding indebtedness and paid an aggregate of $188 million in make-whole premiums in connection with those redemptions, plus accrued and unpaid interest. The payment of these make-whole premiums, net of certain deferred gains of $9 million , are reflected as a loss on early extinguishment of borrowings in the accompanying Consolidated Condensed Statement of Earnings of $179 million ( $112 million after-tax or 0.16 per diluted share) in the three and nine -month periods ended September 30, 2016 .

Restructuring (Notes)

Restructuring (Notes)	9 Months Ended
	Sep. 29, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure	RESTRUCTURING For additional details regarding the Company’s restructuring activities, reference is made to Note 14 of the Company’s financial statements as of and for the year ended December 31, 2016 included in the Company’s 2016 Annual Report. During the nine-month period ended September 29, 2017 , the Company made the strategic decision to discontinue a molecular diagnostic product line in its Diagnostics segment. As a result, the Company recorded $76 million of pretax restructuring, impairment and other related charges ( $51 million after-tax or $0.07 per diluted share). These charges included $49 million of noncash charges for the impairment of certain technology-related intangible assets as well as related inventory and property, plant and equipment with no further use. In addition, the Company incurred $27 million of cash restructuring costs primarily related to employee severance and related charges. Substantially all restructuring activities related to this discontinued product line were completed in the nine-month period ended September 29, 2017 . The restructuring, impairment and other related charges incurred during the nine-month period ended September 29, 2017 related to the discontinued product line in the Diagnostics segment are reflected in the following captions in the accompanying Consolidated Condensed Statement of Earnings ($ in millions): Cost of sales $ 20.7 Selling, general and administrative expenses 55.2 Total $ 75.9

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 29, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES For a description of the Company’s litigation and contingencies, reference is made to Note 16 of the Company’s financial statements as of and for the year ended December 31, 2016 included in the Company’s 2016 Annual Report. The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance, December 31, 2016 $ 75.8 Accruals for warranties issued during the period 36.0 Settlements made (42.0 ) Additions due to acquisitions 1.3 Effect of foreign currency translation 3.4 Balance, September 29, 2017 $ 74.5

Net Earnings Per Share From Con

Net Earnings Per Share From Continuing Operations	9 Months Ended
	Sep. 29, 2017
Earnings Per Share [Abstract]
Net Earnings Per Share From Continuing Operations	NET EARNINGS PER SHARE FROM CONTINUING OPERATIONS Basic net earnings per share (“EPS”) from continuing operations is calculated by dividing net earnings from continuing operations by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS from continuing operations is computed based on the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three and nine -month periods ended September 29, 2017 , approximately four million options to purchase shares were not included in the diluted EPS from continuing operations calculation as the impact of their inclusion would have been anti-dilutive. For both the three and nine -month periods ended September 30, 2016 there were no anti-dilutive options to purchase shares excluded from the diluted EPS from continuing operations calculation. Information related to the calculation of net earnings per share from continuing operations is summarized as follows ($ and shares in millions, except per share amounts): Net Earnings from Continuing Operations Shares Per Share Amount For the Three-Month Period Ended September 29, 2017: Basic EPS $ 572.1 696.2 $ 0.82 Adjustment for interest on convertible debentures 0.6 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 6.5 Incremental shares from assumed conversion of the convertible debentures — 2.9 Diluted EPS $ 572.7 705.6 $ 0.81 For the Three-Month Period Ended September 30, 2016: Basic EPS $ 402.6 692.2 $ 0.58 Adjustment for interest on convertible debentures 0.5 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 6.2 Incremental shares from assumed conversion of the convertible debentures — 2.9 Diluted EPS $ 403.1 701.3 $ 0.57 For the Nine-Month Period Ended September 29, 2017: Basic EPS $ 1,613.2 695.3 $ 2.32 Adjustment for interest on convertible debentures 1.6 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 7.3 Incremental shares from assumed conversion of the convertible debentures — 2.9 Diluted EPS $ 1,614.8 705.5 $ 2.29 For the Nine-Month Period Ended September 30, 2016: Basic EPS $ 1,406.4 690.6 $ 2.04 Adjustment for interest on convertible debentures 1.4 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 6.0 Incremental shares from assumed conversion of the convertible debentures — 2.5 Diluted EPS $ 1,407.8 699.1 $ 2.01

Segment Information

Segment Information	9 Months Ended
	Sep. 29, 2017
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company operates and reports its results in four separate business segments consisting of the Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. There has been no material change in total assets or liabilities by segment since December 31, 2016 . Segment results are shown below ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Sales: Life Sciences $ 1,392.6 $ 1,325.4 $ 4,085.0 $ 3,911.8 Diagnostics 1,448.7 1,212.7 4,216.0 3,606.5 Dental 694.0 675.6 2,052.1 2,046.1 Environmental & Applied Solutions 992.9 918.4 2,890.9 2,733.7 Total $ 4,528.2 $ 4,132.1 $ 13,244.0 $ 12,298.1 Operating profit: Life Sciences $ 246.8 $ 204.7 $ 680.0 $ 574.1 Diagnostics 242.7 193.9 554.9 606.3 Dental 102.2 101.3 301.4 305.6 Environmental & Applied Solutions 222.8 223.4 666.0 640.1 Other (47.0 ) (24.2 ) (127.2 ) (103.8 ) Total $ 767.5 $ 699.1 $ 2,075.1 $ 2,022.3

General (Policies)

General (Policies)	9 Months Ended
	Sep. 29, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Standards	New Accounting Standards —In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which provided clarity on which changes to the terms or conditions of share-based payment awards require an entity to apply the modification accounting provisions required in Topic 718. The standard is effective for all entities for annual periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company does not expect the adoption of this ASU will have a material impact on its consolidated financial statements. In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost , which requires employers to disaggregate the service cost component from other components of net periodic benefit costs and to disclose the amounts of net periodic benefit costs that are included in each income statement line item. The standard requires employers to report the service cost component in the same line item as other compensation costs and to report the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. The income statement guidance requires application on a retrospective basis. The ASU is effective for public entities for annual periods beginning after December 15, 2017, including interim periods, with early adoption permitted. The Company does not expect the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718) , which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification of certain items on the statement of cash flows and accounting for forfeitures. The Company has adopted this standard effective January 1, 2017. The ASU requires that the difference between the actual tax benefit realized upon exercise or vesting, as applicable, and the tax benefit recorded based on the fair value of the stock award at the time of grant (the “excess tax benefits”) be reflected as a reduction of the current period provision for income taxes with any shortfall recorded as an increase in the tax provision rather than as a component of changes to additional paid-in capital. The ASU also requires the excess tax benefit realized be reflected as operating cash flow rather than a financing cash flow. For the three and nine -month periods ended September 29, 2017 , the provision for income taxes from continuing operations was reduced and operating cash flow from continuing operations was increased by $7 million and $40 million , respectively, reflecting the impact of adopting this standard. Had this ASU been adopted at January 1, 2016, the provision for income taxes from continuing operations would have been reduced and operating cash flow from continuing operations would have been increased by $8 million and $34 million from the amounts reported for the three and nine -month periods ended September 30, 2016 , respectively. The actual benefit to be realized in future periods is inherently uncertain and will vary based on the price of the Company’s common stock as well as the timing of and relative value realized for future share-based transactions. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which requires lessees to recognize a right-of-use asset and a lease liability for all leases with terms greater than 12 months. The standard also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. The ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. In September 2017, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which provided additional implementation guidance on the previously issued ASU . Management has not yet completed its assessment of the impact of the new standard on the Company’s consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The ASU amends guidance on the classification and measurement of financial instruments, including significant revisions in accounting related to the classification and measurement of investments in equity securities and presentation of certain fair value changes for financial liabilities when the fair value option is elected. The ASU requires equity securities to be measured at fair value with changes in fair value recognized through net earnings and amends certain disclosure requirements associated with the fair value of financial instruments. The ASU is effective for the Company on January 1, 2018. In the period of adoption, the Company is required to reclassify the unrealized gains/losses on equity securities within accumulated other comprehensive income (loss) to retained earnings, which is not expected to be material to the Company’s consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , which supersedes nearly all existing revenue recognition guidance. The core principle of Topic 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of the standard by one year which results in the new standard being effective for the Company at the beginning of its first quarter of fiscal year 2018. In addition, during March, April, May and December 2016 and September 2017, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, and ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), respectively, which clarified the guidance on certain items such as reporting revenue as a principal versus agent, identifying performance obligations, accounting for intellectual property licenses, assessing collectability, presentation of sales taxes, impairment testing for contract costs, disclosure of performance obligations, and provided additional implementation guidance. The Company plans to adopt the new standard on January 1, 2018. The Company has completed its initial assessment of the effect of adoption. Based on this assessment, the Company expects the impact of the new standard on the amount and timing of revenue recognition to be insignificant. The new standard will require certain costs, primarily sales-related commissions on contracts greater than one year in duration, to be capitalized rather than expensed currently. The new standard will also require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows from customer contracts, including judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The Company has identified, and is in the process of implementing, appropriate changes to its business processes, systems and controls to support recognition and disclosure under the new standard. The Company expects to use the modified retrospective method of adoption, reflecting the cumulative effect of initially applying the new standard to revenue recognition in the first quarter of 2018.

General (Tables)

General (Tables)	9 Months Ended
	Sep. 29, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Components Of Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) —The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. Foreign Currency Translation Adjustments Pension & Postretirement Plan Benefit Adjustments Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments Total For the Three-Month Period Ended September 29, 2017: Balance, June 30, 2017 $ (1,819.0 ) $ (632.4 ) $ 36.9 $ (2,414.5 ) Other comprehensive income (loss) before reclassifications: Increase (decrease) 260.0 — (3.0 ) 257.0 Income tax impact — — 1.1 1.1 Other comprehensive income (loss) before reclassifications, net of income taxes 260.0 — (1.9 ) 258.1 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 7.0 (a) — 7.0 Income tax impact — (2.4 ) — (2.4 ) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 4.6 — 4.6 Net current period other comprehensive income (loss), net of income taxes 260.0 4.6 (1.9 ) 262.7 Balance, September 29, 2017 $ (1,559.0 ) $ (627.8 ) $ 35.0 $ (2,151.8 ) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 7 for additional details. Foreign Currency Translation Adjustments Pension & Postretirement Plan Benefit Adjustments Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments Total For the Three-Month Period Ended September 30, 2016: Balance, July 1, 2016 $ (1,758.2 ) $ (636.2 ) $ 3.2 $ (2,391.2 ) Other comprehensive income (loss) before reclassifications: Increase 275.6 — 13.9 289.5 Income tax impact — — (5.1 ) (5.1 ) Other comprehensive income (loss) before reclassifications, net of income taxes 275.6 — 8.8 284.4 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 7.2 (a) — 7.2 Income tax impact — (2.5 ) — (2.5 ) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 4.7 — 4.7 Net current period other comprehensive income (loss), net of income taxes 275.6 4.7 8.8 289.1 Distribution of Fortive Corporation (83.5 ) 63.3 (c) — (20.2 ) Balance, September 30, 2016 $ (1,566.1 ) $ (568.2 ) $ 12.0 $ (2,122.3 ) For the Nine-Month Period Ended September 29, 2017: Balance, December 31, 2016 $ (2,398.2 ) $ (642.2 ) $ 18.7 $ (3,021.7 ) Other comprehensive income (loss) before reclassifications: Increase 839.2 — 26.1 865.3 Income tax impact — — (9.8 ) (9.8 ) Other comprehensive income (loss) before reclassifications, net of income taxes 839.2 — 16.3 855.5 Amounts reclassified from accumulated other comprehensive income (loss): Increase — 22.2 (a) — 22.2 Income tax impact — (7.8 ) — (7.8 ) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 14.4 — 14.4 Net current period other comprehensive income (loss), net of income taxes 839.2 14.4 16.3 869.9 Balance, September 29, 2017 $ (1,559.0 ) $ (627.8 ) $ 35.0 $ (2,151.8 ) For the Nine-Month Period Ended September 30, 2016: Balance, December 31, 2015 $ (1,797.4 ) $ (647.3 ) $ 133.5 $ (2,311.2 ) Other comprehensive income (loss) before reclassifications: Increase 314.8 — 28.8 343.6 Income tax impact — — (10.7 ) (10.7 ) Other comprehensive income (loss) before reclassifications, net of income taxes 314.8 — 18.1 332.9 Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 23.6 (a) (223.4 ) (b) (199.8 ) Income tax impact — (7.8 ) 83.8 76.0 Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 15.8 (139.6 ) (123.8 ) Net current period other comprehensive income (loss), net of income taxes 314.8 15.8 (121.5 ) 209.1 Distribution of Fortive Corporation (83.5 ) 63.3 (c) — (20.2 ) Balance, September 30, 2016 $ (1,566.1 ) $ (568.2 ) $ 12.0 $ (2,122.3 ) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 7 for additional details. (b) Included in other income in the accompanying Consolidated Condensed Statement of Earnings. Refer to Note 10 for additional details. (c) This accumulated other comprehensive income (loss) component included an income tax impact of $21 million .

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 29, 2017
Business Combinations [Abstract]
Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for all acquisitions consummated during the nine -month period ended September 29, 2017 ($ in millions): Trade accounts receivable $ 8.7 Inventories 13.2 Property, plant and equipment 4.9 Goodwill 73.2 Other intangible assets, primarily customer relationships, trade names and technology 52.5 Trade accounts payable (4.1 ) Other assets and liabilities, net (36.4 ) Net cash consideration $ 112.0
Results Of Operations If Acquisition Was Consummated	The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Sales $ 4,528.5 $ 4,327.2 $ 13,269.4 $ 12,883.7 Net earnings from continuing operations 572.1 367.8 1,613.2 1,287.2 Diluted net earnings per share from continuing operations 0.81 0.53 2.29 1.84

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 29, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule Of Disposal Group Including Discontinued Operations	The key components of income from discontinued operations for the three-month period ended September 30, 2016 and the nine -month periods ended September 29, 2017 and September 30, 2016 were as follows ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 30, 2016 September 29, 2017 September 30, 2016 Sales $ — $ — $ 3,029.8 Cost of sales — — (1,566.4 ) Selling, general and administrative expenses (16.4 ) — (696.0 ) Research and development expenses — — (190.4 ) Interest expense — — (19.7 ) Earnings from discontinued operations before income taxes (16.4 ) — 557.3 Income taxes 5.4 22.3 (157.0 ) Earnings from discontinued operations, net of income taxes $ (11.0 ) $ 22.3 $ 400.3

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 29, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward Of Goodwill	The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2016 $ 23,826.9 Attributable to 2017 acquisitions 73.2 Adjustments due to finalization of purchase price allocations (71.3 ) Foreign currency translation and other 955.0 Balance, September 29, 2017 $ 24,783.8 The carrying value of goodwill by segment is summarized as follows ($ in millions): September 29, 2017 December 31, 2016 Life Sciences $ 12,153.9 $ 11,610.3 Diagnostics 7,049.0 6,903.0 Dental 3,341.1 3,215.6 Environmental & Applied Solutions 2,239.8 2,098.0 Total $ 24,783.8 $ 23,826.9

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 29, 2017
Fair Value Disclosures [Abstract]
Financial Assets And Liabilities Carried At Fair Value	A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total September 29, 2017: Assets: Available-for-sale securities $ 143.6 $ 47.1 $ — $ 190.7 Liabilities: Deferred compensation plans — 59.3 — 59.3 December 31, 2016: Assets: Available-for-sale securities $ 117.8 $ 52.3 $ — $ 170.1 Liabilities: Deferred compensation plans — 52.2 — 52.2
Carrying Amounts And Fair Values Of Financial Instruments	The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): September 29, 2017 December 31, 2016 Carrying Amount Fair Value Carrying Amount Fair Value Assets: Available-for-sale securities $ 190.7 $ 190.7 $ 170.1 $ 170.1 Liabilities: Notes payable and current portion of long-term debt 182.2 182.2 2,594.8 2,594.8 Long-term debt 10,726.8 11,181.4 9,674.2 10,095.1

Financing (Tables)

Financing (Tables)	9 Months Ended
	Sep. 29, 2017
Debt Disclosure [Abstract]
Components Of Debt	The components of the Company’s debt were as follows ($ in millions): September 29, 2017 December 31, 2016 U.S. dollar-denominated commercial paper $ 190.0 $ 2,733.5 Euro-denominated commercial paper (€2.3 billion and €3.0 billion, respectively) 2,692.1 3,127.6 Floating rate senior unsecured notes due 2017 (€500.0 million aggregate principal amount) (the “2017 Euronotes”) — 526.0 0.0% senior unsecured bonds due 2017 (CHF 100.0 million aggregate principal amount) (the “2017 CHF Bonds”) 103.1 98.0 1.65% senior unsecured notes due 2018 499.0 498.1 1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”) 706.9 628.6 2.4% senior unsecured notes due 2020 497.5 496.8 5.0% senior unsecured notes due 2020 398.5 402.6 Zero-coupon Liquid Yield Option Notes (LYONs) due 2021 68.7 68.1 0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) 265.7 255.6 1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”) 940.5 836.5 Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) 294.4 — 0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”) 559.6 532.3 2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”) 940.5 836.8 3.35% senior unsecured notes due 2025 496.2 495.8 0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) 272.5 — 1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”) 702.8 — 1.125% senior unsecured bonds due 2028 (CHF 110.0 million aggregate principal amount) (the “2028 CHF Bonds”) 114.4 108.8 0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) 470.6 — 4.375% senior unsecured notes due 2045 499.3 499.3 Other 196.7 124.6 Total debt 10,909.0 12,269.0 Less: currently payable 182.2 2,594.8 Long-term debt $ 10,726.8 $ 9,674.2

Defined Benefit Plans (Tables)

Defined Benefit Plans (Tables)	9 Months Ended
	Sep. 29, 2017
Defined benefit pension plans
Defined Benefit Plan Disclosure
Schedule of Net Benefit Costs	The following sets forth the components of the Company’s net periodic benefit cost of the noncontributory defined benefit pension plans ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 U.S. Pension Benefits: Service cost $ 1.9 $ 2.2 $ 5.7 $ 6.8 Interest cost 20.1 22.3 62.1 67.7 Expected return on plan assets (32.4 ) (33.0 ) (98.2 ) (99.6 ) Amortization of actuarial loss 5.9 6.3 19.1 18.3 Curtailment gain recognized — — — (0.7 ) Net periodic pension cost $ (4.5 ) $ (2.2 ) $ (11.3 ) $ (7.5 ) Non-U.S. Pension Benefits: Service cost $ 8.1 $ 9.0 $ 23.7 $ 26.9 Interest cost 6.7 8.4 19.5 25.8 Expected return on plan assets (10.8 ) (9.9 ) (31.5 ) (30.8 ) Amortization of actuarial loss 2.0 1.9 5.8 8.5 Amortization of prior service credit (0.1 ) (0.1 ) (0.3 ) (0.3 ) Settlement loss recognized — — — 0.1 Net periodic pension cost $ 5.9 $ 9.3 $ 17.2 $ 30.2
Other postretirement benefit plans
Defined Benefit Plan Disclosure
Schedule of Net Benefit Costs	The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee benefit plans ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Service cost $ 0.1 $ 0.2 $ 0.5 $ 0.6 Interest cost 1.1 1.4 3.7 4.2 Amortization of actuarial (gain) loss — (0.1 ) — 0.1 Amortization of prior service credit (0.8 ) (0.8 ) (2.4 ) (2.4 ) Net periodic benefit cost $ 0.4 $ 0.7 $ 1.8 $ 2.5

Stock Transactions And Stock-29

Stock Transactions And Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 29, 2017
Share-based Compensation [Abstract]
Components Of Stock-Based Compensation Program	The following summarizes the components of the Company’s stock-based compensation expense ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Restricted stock units (“RSUs”)/performance stock units (“PSUs”): Pretax compensation expense $ 21.9 $ 21.1 $ 67.6 $ 65.0 Income tax benefit (6.6 ) (6.2 ) (20.7 ) (19.1 ) RSU/PSU expense, net of income taxes 15.3 14.9 46.9 45.9 Stock options: Pretax compensation expense 11.5 10.3 37.2 31.3 Income tax benefit (3.6 ) (3.2 ) (11.8 ) (9.7 ) Stock option expense, net of income taxes 7.9 7.1 25.4 21.6 Total stock-based compensation: Pretax compensation expense 33.4 31.4 104.8 96.3 Income tax benefit (10.2 ) (9.4 ) (32.5 ) (28.8 ) Total stock-based compensation expense, net of income taxes $ 23.2 $ 22.0 $ 72.3 $ 67.5

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 29, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The restructuring, impairment and other related charges incurred during the nine-month period ended September 29, 2017 related to the discontinued product line in the Diagnostics segment are reflected in the following captions in the accompanying Consolidated Condensed Statement of Earnings ($ in millions): Cost of sales $ 20.7 Selling, general and administrative expenses 55.2 Total $ 75.9

Commitments And Contingencies (

Commitments And Contingencies (Tables)	9 Months Ended
	Sep. 29, 2017
Commitments and Contingencies Disclosure [Abstract]
Warranty Accrual	The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance, December 31, 2016 $ 75.8 Accruals for warranties issued during the period 36.0 Settlements made (42.0 ) Additions due to acquisitions 1.3 Effect of foreign currency translation 3.4 Balance, September 29, 2017 $ 74.5

Net Earnings Per Share From C32

Net Earnings Per Share From Continuing Operations (Tables)	9 Months Ended
	Sep. 29, 2017
Earnings Per Share [Abstract]
Components Of Basic And Diluted Earnings Per Share	Information related to the calculation of net earnings per share from continuing operations is summarized as follows ($ and shares in millions, except per share amounts): Net Earnings from Continuing Operations Shares Per Share Amount For the Three-Month Period Ended September 29, 2017: Basic EPS $ 572.1 696.2 $ 0.82 Adjustment for interest on convertible debentures 0.6 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 6.5 Incremental shares from assumed conversion of the convertible debentures — 2.9 Diluted EPS $ 572.7 705.6 $ 0.81 For the Three-Month Period Ended September 30, 2016: Basic EPS $ 402.6 692.2 $ 0.58 Adjustment for interest on convertible debentures 0.5 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 6.2 Incremental shares from assumed conversion of the convertible debentures — 2.9 Diluted EPS $ 403.1 701.3 $ 0.57 For the Nine-Month Period Ended September 29, 2017: Basic EPS $ 1,613.2 695.3 $ 2.32 Adjustment for interest on convertible debentures 1.6 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 7.3 Incremental shares from assumed conversion of the convertible debentures — 2.9 Diluted EPS $ 1,614.8 705.5 $ 2.29 For the Nine-Month Period Ended September 30, 2016: Basic EPS $ 1,406.4 690.6 $ 2.04 Adjustment for interest on convertible debentures 1.4 — Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs — 6.0 Incremental shares from assumed conversion of the convertible debentures — 2.5 Diluted EPS $ 1,407.8 699.1 $ 2.01

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 29, 2017
Segment Reporting [Abstract]
Segment Results	Segment results are shown below ($ in millions): Three-Month Period Ended Nine-Month Period Ended September 29, 2017 September 30, 2016 September 29, 2017 September 30, 2016 Sales: Life Sciences $ 1,392.6 $ 1,325.4 $ 4,085.0 $ 3,911.8 Diagnostics 1,448.7 1,212.7 4,216.0 3,606.5 Dental 694.0 675.6 2,052.1 2,046.1 Environmental & Applied Solutions 992.9 918.4 2,890.9 2,733.7 Total $ 4,528.2 $ 4,132.1 $ 13,244.0 $ 12,298.1 Operating profit: Life Sciences $ 246.8 $ 204.7 $ 680.0 $ 574.1 Diagnostics 242.7 193.9 554.9 606.3 Dental 102.2 101.3 301.4 305.6 Environmental & Applied Solutions 222.8 223.4 666.0 640.1 Other (47.0 ) (24.2 ) (127.2 ) (103.8 ) Total $ 767.5 $ 699.1 $ 2,075.1 $ 2,022.3

General New Accounting Standard

General New Accounting Standards (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New accounting pronouncement, effect of adoption, compensation-stock compensation	$ 7	$ 8	$ 40	$ 34

General (Components of Accumula

General (Components of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance			$ (3,021.7)
Total other comprehensive income (loss), net of income taxes	$ 262.7	$ 289.1	869.9	$ 209.1
Ending balance	(2,151.8)		(2,151.8)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(1,819)	(1,758.2)	(2,398.2)	(1,797.4)
Increase (decrease)	260	275.6	839.2	314.8
Income tax impact	0	0	0	0
Other comprehensive income (loss) before reclassifications, net of income taxes	260	275.6	839.2	314.8
Increase (decrease)	0	0	0	0
Income tax impact	0	0	0	0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0	0	0	0
Total other comprehensive income (loss), net of income taxes	260	275.6	839.2	314.8
Distribution of Fortive Corporation		(83.5)		(83.5)
Ending balance	(1,559)	(1,566.1)	(1,559)	(1,566.1)
Pension and postretirement plan benefit adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(632.4)	(636.2)	(642.2)	(647.3)
Increase (decrease)	0	0	0	0
Income tax impact	0	0	0	0
Other comprehensive income (loss) before reclassifications, net of income taxes	0	0	0	0
Increase (decrease)	7	7.2	22.2	23.6
Income tax impact	(2.4)	(2.5)	(7.8)	(7.8)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	4.6	4.7	14.4	15.8
Total other comprehensive income (loss), net of income taxes	4.6	4.7	14.4	15.8
Distribution of Fortive Corporation		63.3		63.3
Ending balance	(627.8)	(568.2)	(627.8)	(568.2)
Distribution of Fortive Corporation, income tax impact				21
Unrealized Gain (Loss) on Available-For-Sale Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	36.9	3.2	18.7	133.5
Increase (decrease)	(3)	13.9	26.1	28.8
Income tax impact	1.1	(5.1)	(9.8)	(10.7)
Other comprehensive income (loss) before reclassifications, net of income taxes	(1.9)	8.8	16.3	18.1
Increase (decrease)	0	0	0	(223.4)
Income tax impact	0	0	0	83.8
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0	0	0	(139.6)
Total other comprehensive income (loss), net of income taxes	(1.9)	8.8	16.3	(121.5)
Distribution of Fortive Corporation		0		0
Ending balance	35	12	35	12
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(2,414.5)	(2,391.2)	(3,021.7)	(2,311.2)
Increase (decrease)	257	289.5	865.3	343.6
Income tax impact	1.1	(5.1)	(9.8)	(10.7)
Other comprehensive income (loss) before reclassifications, net of income taxes	258.1	284.4	855.5	332.9
Increase (decrease)	7	7.2	22.2	(199.8)
Income tax impact	(2.4)	(2.5)	(7.8)	76
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	4.6	4.7	14.4	(123.8)
Total other comprehensive income (loss), net of income taxes	262.7	289.1	869.9	209.1
Distribution of Fortive Corporation		(20.2)		(20.2)
Ending balance	$ (2,151.8)	$ (2,122.3)	$ (2,151.8)	$ (2,122.3)

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2017USD ($)	Sep. 29, 2017USD ($)Businesses	Sep. 30, 2016USD ($)
Business Acquisition [Line Items]
Number of businesses acquired | Businesses		5
Net cash consideration		$ 112	$ 99.6
Revenue reported by acquired entity for last annual period		70
Goodwill		73.2
Payment for purchase of noncontrolling interests	$ 64	$ 64.4	0
Decrease in noncontrolling interests	(63)
Decrease in additional paid-in capital	$ (1)
Fair value adjustment to inventory | Cepheid
Business Acquisition [Line Items]
Fair value adjustment to inventory			$ 23

Acquisitions Fair Values Of The

Acquisitions Fair Values Of The Assets Acquired And Liabilities Assumed (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016
Business Combinations [Abstract]
Trade accounts receivable	$ 8.7
Inventories	13.2
Property, plant and equipment	4.9
Goodwill	73.2
Other intangible assets, primarily customer relationships, trade names and technology	52.5
Trade accounts payable	(4.1)
Other assets and liabilities, net	(36.4)
Net cash consideration	$ 112	$ 99.6

Acquisitions (Results Of Operat

Acquisitions (Results Of Operations If Acquisition Was Consummated) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Business Combinations [Abstract]
Sales	$ 4,528.5	$ 4,327.2	$ 13,269.4	$ 12,883.7
Net earnings from continuing operations	$ 572.1	$ 367.8	$ 1,613.2	$ 1,287.2
Diluted net earnings per share from continuing operations	$ 0.81	$ 0.53	$ 2.29	$ 1.84

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]
Income tax benefit	$ (5.4)	$ (22.3)	$ 157

Discontinued Operations (Compon

Discontinued Operations (Components Of Income Related To Discontinued Operations) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Sales		$ 0	$ 0	$ 3,029.8
Cost of sales		0	0	(1,566.4)
Selling, general and administrative expenses		(16.4)	0	(696)
Research and development expenses		0	0	(190.4)
Interest expense		0	0	(19.7)
Earnings from discontinued operations before income taxes		(16.4)	0	557.3
Income taxes		5.4	22.3	(157)
Earnings from discontinued operations, net of income taxes	$ 0	$ (11)	$ 22.3	$ 400.3

Goodwill (Rollforward Of Goodwi

Goodwill (Rollforward Of Goodwill) (Details) $ in Millions	9 Months Ended
	Sep. 29, 2017USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 23,826.9
Attributable to 2017 acquisitions	73.2
Adjustments due to finalization of purchase price allocations	(71.3)
Foreign currency translation and other	955
Ending balance	$ 24,783.8

Goodwill (Goodwill By Segment)

Goodwill (Goodwill By Segment) (Details) - USD ($) $ in Millions	Sep. 29, 2017	Dec. 31, 2016
Goodwill [Line Items]
Total goodwill	$ 24,783.8	$ 23,826.9
Operating segments | Life Sciences
Goodwill [Line Items]
Total goodwill	12,153.9	11,610.3
Operating segments | Diagnostics
Goodwill [Line Items]
Total goodwill	7,049	6,903
Operating segments | Dental
Goodwill [Line Items]
Total goodwill	3,341.1	3,215.6
Operating segments | Environmental & Applied Solutions
Goodwill [Line Items]
Total goodwill	$ 2,239.8	$ 2,098

Fair Value Measurements (Financ

Fair Value Measurements (Financial Assets And Liabilities Carried At Fair Value) (Details) - USD ($) $ in Millions	Sep. 29, 2017	Dec. 31, 2016
Assets:
Available-for-sale securities	$ 190.7	$ 170.1
Liabilities:
Deferred compensation plans	59.3	52.2
Quoted Prices in Active Market (Level 1)
Assets:
Available-for-sale securities	143.6	117.8
Liabilities:
Deferred compensation plans	0	0
Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale securities	47.1	52.3
Liabilities:
Deferred compensation plans	59.3	52.2
Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale securities	0	0
Liabilities:
Deferred compensation plans	$ 0	$ 0

Fair Value Measurements (Carryi

Fair Value Measurements (Carrying Amounts And Fair Values Of Financial Instruments) (Details) - USD ($) $ in Millions	Sep. 29, 2017	Dec. 31, 2016
Assets:
Available-for-sale securities, carrying amount	$ 190.7	$ 170.1
Available-for-sale securities, fair value	190.7	170.1
Liabilities:
Notes payable and current portion of long-term debt	182.2	2,594.8
Long-term debt	10,726.8	9,674.2
Notes payable and current portion of long-term debt, fair value	182.2	2,594.8
Long-term debt, fair value	$ 11,181.4	$ 10,095.1

Financing (Narrative) (Details)

Financing (Narrative) (Details) $ / shares in Units, shares in Thousands, € in Millions, ¥ in Billions	Sep. 29, 2017JPY (¥)	Jun. 30, 2017USD ($)	Jun. 30, 2017EUR (€)	May 11, 2017JPY (¥)	May 11, 2017USD ($)	Sep. 29, 2017JPY (¥)shares	Sep. 29, 2017USD ($)$ / shares	Sep. 29, 2017EUR (€)	Jun. 23, 2017USD ($)	Apr. 21, 2017USD ($)	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2016EUR (€)	Oct. 31, 2016USD ($)
Debt Instrument [Line Items]
Long-term debt							$ 10,909,000,000				$ 12,269,000,000
Debt discounts, premiums and debt issuance costs							$ 31,000,000				$ 25,000,000
Common stock, par value | $ / shares							$ 0.01				$ 0.01
Senior notes | 0.65% senior unsecured notes due 2032
Debt Instrument [Line Items]
Long-term debt							$ 470,600,000				$ 0
Debt instrument, face value | ¥	¥ 53.2			¥ 53.2		¥ 53.2
Interest rate of debt instrument	0.65%			0.65%		0.65%	0.65%	0.65%
Debt instrument, redemption price, percentage				100.00%	100.00%
Senior notes | 2027 and 2032 Yen notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%
Net proceeds from debt				¥ 83.6	$ 744,000,000
Senior notes | Floating rate senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt							$ 294,400,000				0
Debt instrument, face value | €			€ 250					€ 250
Debt instrument, basis spread on variable rate		0.30%	0.30%
Debt instrument, redemption price, percentage		100.147%	100.147%
Senior notes | 1.2% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt							$ 702,800,000				0
Debt instrument, face value | €			€ 600					€ 600
Interest rate of debt instrument	1.20%		1.20%			1.20%	1.20%	1.20%
Debt instrument, redemption price, percentage		99.682%	99.682%
Senior notes | Euronotes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	101.00%
Net proceeds from debt		$ 940,000,000	€ 843
Senior notes | Floating rate senior unsecured notes due 2017
Debt Instrument [Line Items]
Long-term debt							$ 0				526,000,000
Debt instrument, face value | €								€ 0				€ 500
Senior notes | 0.3% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt							$ 272,500,000				0
Debt instrument, face value | ¥	¥ 30.8			¥ 30.8		¥ 30.8
Interest rate of debt instrument	0.30%			0.30%		0.30%	0.30%	0.30%
Debt instrument, redemption price, percentage				100.00%	100.00%
Convertible debt | Zero-coupon LYONs due 2021
Debt Instrument [Line Items]
Long-term debt							$ 68,700,000				$ 68,100,000
Interest rate of debt instrument	0.00%					0.00%	0.00%	0.00%
Shares issued under debt conversion, shares | shares						27
Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate of long-term debt, interest rate	0.20%					0.20%	0.20%	0.20%
Weighted average maturity of long-term debt, term	64 days
Long-term debt							$ 2,900,000,000
Revolving credit facility
Debt Instrument [Line Items]
Line of credit facility, amount outstanding							0
Long-term debt | Revolving credit facility | Credit facility
Debt Instrument [Line Items]
Line of credit							$ 4,000,000,000
Short-term debt | Revolving credit facility | 364-day facility
Debt Instrument [Line Items]
Line of credit									$ 1,000,000,000	$ 2,300,000,000			$ 3,000,000,000
Minimum | Senior notes | Floating rate senior unsecured notes due 2022
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage			0.00%

Financing (Components Of Debt)

Financing (Components Of Debt) (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Sep. 29, 2017CHF (SFr)	Sep. 29, 2017JPY (¥)	Sep. 29, 2017USD ($)	Sep. 29, 2017EUR (€)	Jun. 30, 2017EUR (€)	May 11, 2017JPY (¥)	Dec. 31, 2016CHF (SFr)	Dec. 31, 2016JPY (¥)	Dec. 31, 2016USD ($)	Dec. 31, 2016EUR (€)
Debt Instrument [Line Items]
Long-term debt			$ 10,909						$ 12,269
Less: currently payable			182.2						2,594.8
Long-term debt excluding currently payable			10,726.8						9,674.2
Other
Debt Instrument [Line Items]
Long-term debt			196.7						124.6
Commercial paper
Debt Instrument [Line Items]
Long-term debt			2,900
Commercial paper | U.S. dollar-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt			190						2,733.5
Commercial paper | Euro-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt			2,692.1	€ 2,300					3,127.6	€ 3,000
Senior notes | Floating rate senior unsecured notes due 2017
Debt Instrument [Line Items]
Long-term debt			0						526
Debt instrument, face value | €				€ 0						500
Senior notes | 1.65% senior unsecured notes due 2018
Debt Instrument [Line Items]
Long-term debt			$ 499						498.1
Interest rate of debt instrument	1.65%	1.65%	1.65%	1.65%
Senior notes | 1.0% senior unsecured notes due 2019
Debt Instrument [Line Items]
Long-term debt			$ 706.9						628.6
Interest rate of debt instrument	1.00%	1.00%	1.00%	1.00%
Debt instrument, face value | €				€ 600						600
Senior notes | 2.4% senior unsecured notes due 2020
Debt Instrument [Line Items]
Long-term debt			$ 497.5						496.8
Interest rate of debt instrument	2.40%	2.40%	2.40%	2.40%
Senior notes | 5.0% senior notes due 2020
Debt Instrument [Line Items]
Long-term debt			$ 398.5						402.6
Interest rate of debt instrument	5.00%	5.00%	5.00%	5.00%
Senior notes | 0.352% senior unsecured notes due 2021
Debt Instrument [Line Items]
Long-term debt			$ 265.7						255.6
Interest rate of debt instrument	0.352%	0.352%	0.352%	0.352%
Debt instrument, face value | ¥		¥ 30						¥ 30
Senior notes | 1.7% senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt			$ 940.5						836.5
Interest rate of debt instrument	1.70%	1.70%	1.70%	1.70%
Debt instrument, face value | €				€ 800						800
Senior notes | Floating rate senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt			$ 294.4						0
Debt instrument, face value | €				€ 250	€ 250
Senior notes | 2.5% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt			$ 940.5						836.8
Interest rate of debt instrument	2.50%	2.50%	2.50%	2.50%
Debt instrument, face value | €				€ 800						€ 800
Senior notes | 3.35% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt			$ 496.2						495.8
Interest rate of debt instrument	3.35%	3.35%	3.35%	3.35%
Senior notes | 0.3% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt			$ 272.5						0
Interest rate of debt instrument	0.30%	0.30%	0.30%	0.30%		0.30%
Debt instrument, face value | ¥		¥ 30.8				¥ 30.8
Senior notes | 1.2% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt			$ 702.8						0
Interest rate of debt instrument	1.20%	1.20%	1.20%	1.20%	1.20%
Debt instrument, face value | €				€ 600	€ 600
Senior notes | 0.65% senior unsecured notes due 2032
Debt Instrument [Line Items]
Long-term debt			$ 470.6						0
Interest rate of debt instrument	0.65%	0.65%	0.65%	0.65%		0.65%
Debt instrument, face value | ¥		¥ 53.2				¥ 53.2
Senior notes | 4.375% senior unsecured notes due 2045
Debt Instrument [Line Items]
Long-term debt			$ 499.3						499.3
Interest rate of debt instrument	4.375%	4.375%	4.375%	4.375%
Bonds | 0.0% senior unsecured bonds due 2017
Debt Instrument [Line Items]
Long-term debt			$ 103.1						98
Interest rate of debt instrument	0.00%	0.00%	0.00%	0.00%
Debt instrument, face value | SFr	SFr 100						SFr 100
Bonds | 0.5% senior unsecured bonds due 2023
Debt Instrument [Line Items]
Long-term debt			$ 559.6						532.3
Interest rate of debt instrument	0.50%	0.50%	0.50%	0.50%
Debt instrument, face value | SFr	SFr 540						540
Bonds | 1.125% senior unsecured bonds due 2028
Debt Instrument [Line Items]
Long-term debt			$ 114.4						108.8
Interest rate of debt instrument	1.125%	1.125%	1.125%	1.125%
Debt instrument, face value | SFr	SFr 110						SFr 110
Convertible debt | Zero-coupon LYONs due 2021
Debt Instrument [Line Items]
Long-term debt			$ 68.7						$ 68.1
Interest rate of debt instrument	0.00%	0.00%	0.00%	0.00%

Defined Benefit Plans (Narrativ

Defined Benefit Plans (Narrative) (Details) - Defined benefit pension plans $ in Millions	Sep. 29, 2017USD ($)
U.S.
Defined Benefit Plan Disclosure
Expected future employer contributions, current fiscal year	$ 55
Non-U.S.
Defined Benefit Plan Disclosure
Expected future employer contributions, current fiscal year	$ 40

Defined Benefit Plans (Componen

Defined Benefit Plans (Components Of Net Periodic Benefit Cost Of Defined Benefit Pension Pans) (Details) - Defined benefit pension plans - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
U.S.
Defined Benefit Plan Disclosure
Service cost	$ 1.9	$ 2.2	$ 5.7	$ 6.8
Interest cost	20.1	22.3	62.1	67.7
Expected return on plan assets	(32.4)	(33)	(98.2)	(99.6)
Amortization of actuarial loss	5.9	6.3	19.1	18.3
Curtailment gain recognized	0	0	0	(0.7)
Net periodic pension cost	(4.5)	(2.2)	(11.3)	(7.5)
Non-U.S.
Defined Benefit Plan Disclosure
Service cost	8.1	9	23.7	26.9
Interest cost	6.7	8.4	19.5	25.8
Expected return on plan assets	(10.8)	(9.9)	(31.5)	(30.8)
Amortization of actuarial loss	2	1.9	5.8	8.5
Amortization of prior service credit	(0.1)	(0.1)	(0.3)	(0.3)
Settlement loss recognized	0	0	0	0.1
Net periodic pension cost	$ 5.9	$ 9.3	$ 17.2	$ 30.2

Defined Benefit Plans (Compon49

Defined Benefit Plans (Components Of Net Periodic Benefit Cost Of Other PostRetirement Benefit Pension Pans) (Details) - Other postretirement benefit plans - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Defined Benefit Plan Disclosure
Service cost	$ 0.1	$ 0.2	$ 0.5	$ 0.6
Interest cost	1.1	1.4	3.7	4.2
Amortization of actuarial (gain) loss	0	(0.1)	0	0.1
Amortization of prior service credit	(0.8)	(0.8)	(2.4)	(2.4)
Net periodic benefit cost	$ 0.4	$ 0.7	$ 1.8	$ 2.5

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) DKK in Millions, $ in Millions	Sep. 29, 2017USD ($)	Sep. 29, 2017USD ($)	Sep. 30, 2016	Sep. 29, 2017USD ($)	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2012DKK	Dec. 10, 2013DKK
Income Tax Examination [Line Items]
Effective income tax rate, percent		21.60%	15.50%	17.70%	26.60%
Federal statutory income tax rate, percent				35.00%		35.00%
Effective income tax rate reconciliation, statute of limitations, audit settlements, restructuring, stock-based compensation, percent				3.30%
Effective income tax rate reconciliation early extinguishment of borrowings, percent			(6.00%)		(1.00%)
Effective income tax rate reconciliation, repatriation of earnings and legal entity realignments associated with the separation and gain from sale of marketable equity securities, percent					6.60%
Foreign tax authority
Income Tax Examination [Line Items]
Income tax examination, amount of tax assessments	$ 235	$ 235		$ 235				DKK 1,500
Income tax examination, amount of potential additional tax assessments	$ 139						DKK 874

Stock Transactions And Stock-51

Stock Transactions And Stock-Based Compensation (Narrative) (Details) - USD ($) shares in Millions, $ in Millions	Sep. 29, 2017	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016	Jul. 16, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized shares to be repurchased, shares						20
Stock repurchase program, remaining number of shares authorized to be repurchased, shares	20	20		20
Common shares reserved for issuance under the 2007 Omnibus Incentive Plan, shares	72	72		72
Tax benefit from exercise of stock options		$ 15		$ 64
New accounting pronouncement, effect of adoption, compensation-stock compensation		7	$ 8	40	$ 34
Restricted stock units (“RSUs”)/performance stock units (“PSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 153	153		153
Weighted average period for cost to be recognized	2 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 129	$ 129		$ 129
Weighted average period for cost to be recognized	3 years

Stock Transactions And Stock-52

Stock Transactions And Stock-Based Compensation (Components Of Stock-Based Compensation Program) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	$ 33.4	$ 31.4	$ 104.8	$ 96.3
Income tax benefit	(10.2)	(9.4)	(32.5)	(28.8)
Stock-based compensation expense, net of income taxes	23.2	22	72.3	67.5
Restricted stock units (“RSUs”)/performance stock units (“PSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	21.9	21.1	67.6	65
Income tax benefit	(6.6)	(6.2)	(20.7)	(19.1)
Stock-based compensation expense, net of income taxes	15.3	14.9	46.9	45.9
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	11.5	10.3	37.2	31.3
Income tax benefit	(3.6)	(3.2)	(11.8)	(9.7)
Stock-based compensation expense, net of income taxes	$ 7.9	$ 7.1	$ 25.4	$ 21.6

Nonoperating Income (Expense) (

Nonoperating Income (Expense) (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Apr. 01, 2016	Sep. 29, 2017	Sep. 30, 2016
Component of Operating Income [Abstract]
Proceeds from sale of marketable securities			$ 265	$ 0	$ 264.8
Marketable securities, realized gain					223
Marketable securities, after-tax realized gain					$ 140
Marketable securities, after-tax gain, per diluted share					$ 0.20
Extinguishment of debt, amount		$ 1,900
Make-whole premiums to redeem borrowings prior to maturity		(188)		0	$ (188.1)
Extinguishment of debt, deferred gains		9			9.3
Pretax loss on early extinguishment of borrowings	$ 0	(178.8)		$ 0	$ (178.8)
Extinguishment of debt, loss, net of tax		$ (112)
Extinguishment of debt, loss, per share, net of tax		$ (0.16)

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and impairment charges	$ 49.3	$ 0
Molecular diagnostic product line | Operating segments | Diagnostics
Restructuring Cost and Reserve [Line Items]
Restructuring and other related charges	75.9
Restructuring charges, after-tax	$ 51
Restructuring charges, after-tax, per diluted share	$ 0.07
Restructuring and impairment charges	$ 49
Employee severance and related charges	$ 27

Restructuring (Restructuring Re

Restructuring (Restructuring Reserve by Type of Cost) (Details) - Operating segments - Molecular diagnostic product line - Diagnostics $ in Millions	9 Months Ended
	Sep. 29, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and other related charges	$ 75.9
Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring and other related charges	20.7
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring and other related charges	$ 55.2

Commitments And Contingencies56

Commitments And Contingencies (Narrative) (Details)	9 Months Ended
	Sep. 29, 2017
Minimum
Warranty period, term	90 days

Commitments And Contingencies57

Commitments And Contingencies (Warranty Accrual) (Details) $ in Millions	9 Months Ended
	Sep. 29, 2017USD ($)
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Beginning balance	$ 75.8
Accruals for warranties issued during the period	36
Settlements made	(42)
Additions due to acquisitions	1.3
Effect of foreign currency translation	3.4
Ending balance	$ 74.5

Net Earnings Per Share From C58

Net Earnings Per Share From Continuing Operations (Narrative) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, shares	4	0	4	0

Net Earnings Per Share From C59

Net Earnings Per Share From Continuing Operations (Components Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017	Sep. 30, 2016	Sep. 29, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Basis EPS, net earnings from continuing operations (numerator)	$ 572.1	$ 402.6	$ 1,613.2	$ 1,406.4
Adjustment for interest on convertible debentures, net earnings from continuing operations (numerator)	0.6	0.5	1.6	1.4
Diluted EPS, net earnings from continuing operations (numerator)	$ 572.7	$ 403.1	$ 1,614.8	$ 1,407.8
Basic EPS, shares (denominator)	696.2	692.2	695.3	690.6
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs, shares (denominator)	6.5	6.2	7.3	6
Incremental shares from assumed conversion of the convertible debentures, shares (denominator)	2.9	2.9	2.9	2.5
Diluted EPS, shares (denominator)	705.6	701.3	705.5	699.1
Basis EPS, per share amount	$ 0.82	$ 0.58	$ 2.32	$ 2.04
Diluted EPS, per share amount	$ 0.81	$ 0.57	$ 2.29	$ 2.01

Segment Information (Segment Re

Segment Information (Segment Results) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 29, 2017USD ($)Business_Segments	Sep. 30, 2016USD ($)
Segment Reporting Information [Line Items]
Number of segments reported | Business_Segments			4
Sales	$ 4,528.2	$ 4,132.1	$ 13,244	$ 12,298.1
Operating profit	767.5	699.1	2,075.1	2,022.3
Operating segments | Life Sciences
Segment Reporting Information [Line Items]
Sales	1,392.6	1,325.4	4,085	3,911.8
Operating profit	246.8	204.7	680	574.1
Operating segments | Diagnostics
Segment Reporting Information [Line Items]
Sales	1,448.7	1,212.7	4,216	3,606.5
Operating profit	242.7	193.9	554.9	606.3
Operating segments | Dental
Segment Reporting Information [Line Items]
Sales	694	675.6	2,052.1	2,046.1
Operating profit	102.2	101.3	301.4	305.6
Operating segments | Environmental & Applied Solutions
Segment Reporting Information [Line Items]
Sales	992.9	918.4	2,890.9	2,733.7
Operating profit	222.8	223.4	666	640.1
Other
Segment Reporting Information [Line Items]
Operating profit	$ (47)	$ (24.2)	$ (127.2)	$ (103.8)